Processa Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share of Common Stock (Tables)

3 Months Ended

Mar. 31, 2018

The calculation of the numerator and denominator for basic and diluted net loss per common share is shown in the following table.

	For the three months ended
	March 31,
	2018			2017

Net loss from continuing operations applicable to common stockholders - basic and diluted	$	(1,096,798	)	$	(232,442	)

Total common shares issued and outstanding		35,272,626			31,745,242

Weighted average shares outstanding used in calculating net loss per common share - basic and diluted		35,272,626			31,745,242

Net loss per common share - basic and diluted	$	(0.03	)	$	(0.01	)